Jack Krieger, Ph.D. Email & Phone Number

Atlanta, Ga, Us

Strategy and corp dev for new biotech venture

Biotech company creation and public company investing

Palo Alto, California, Us

I led the Portfolio team to 1) make recommendations to the CEO on portfolio strategy (which drug programs to wholly own vs. transact, and with what economics) and R&D strategy (whether the experimental plan optimizes value and risk) based on scientific and financial diligence of the entire drug portfolio, 2) work closely with drug development program teams to assess and manage R&D risk at the program level, 3) assist business development due diligences for M&A, partnership, and new program opportunities, and 4) ideate and implement special projects to enhance the company's operating model and improve knowledge management.

Palo Alto, California, Us

Palo Alto, California, Us

I co-led with a cross-functional team the end-to-end strategy and operations of our preclinical drug development program for autism spectrum disorder associated with PTEN gene variants (PTEN ASD).

Palo Alto, California, Us

Us

Led McKinsey and client teams on strategic and organizational topics serving pharmaceutical and medical product companies. Drove impact through external and internal stakeholder management, analytical and conceptual problem solving, written and verbal story-lining, coaching teammates, and rigorous project managementR&D: - Framed portfolio optimization decisions and R&D strategy decisions for a top pharmaco, leading 2 consultants to help 5 cross-functional TA development teams evaluate >30 clinical development programs (~$1B expense) via novel methodology- Led R&D portfolio prioritization workstreams at 2 different Fortune 500 pharmaceutical and medical product companies, which have implemented the underlying processes- Co-developed integrated evidence generation strategies/plans for 3 hematology pipeline assets, managing team of 4 consultants to help medical affairs at top pharmaco improve and champion a new cross-functional processStrategy and growth:- Enabled >$7B acquisition of oncology therapeutics company through outside-in due diligence; performed financial and qualitative evaluation of multiple biomarker-dependent assets across various tumor types- Segmented patients and providers for immunology drug launch (>$200M annual rev.) using machine learning and managing team of 7 data scientists/engineers across internal and client organizations; translated business questions into technical approaches and analytical results into synthesized business insights- Identified list price reduction strategies for market access organization of a Fortune 500 pharmacoOrganizational effectiveness:- Designed top-level organizational structure and governance for autologous cell therapy business of a leading pharmaco; determined key success factors for go-to-market model and digital patient/provider solution- Designed enterprise level R&D, medical affairs, and marketing operating models at 3 different Fortune 500 pharmaceutical and medical products companies

Us

Atlanta, Georgia , Us

Laboratory for Immuno-Regenerative Engineering | Dr. Edward BotchweyEvaluated the relationship between immune cell subset activity, vascular remodeling, and soft tissue healing. Co-developed novel biomaterials to control immune cell subsets in situ and promote vascular remodeling and soft tissue repair.Collaboration:- Led new interdisciplinary collaboration between 2 labs through stakeholder alignment, hypothesis generation, delegation and project management, experimental execution, and synthesis of results - Published 5 papers (4 first-author) thereby enabling collaborator to win >$1M NIH R01 grant award- Forged another new collaboration across institutions and drove project from ideation to first-author publication in 1 yearCommunication: Published 8 peer-reviewed papers (6 first-author) and delivered several oral and poster presentationsResourcing: Led end-to-end conception and writing of 5-year >$1M NIH R01 grant proposal that received top 25% rankingLeadership: Conceived and guided 4 undergrad research projects that aligned students’ personal goals with laboratory’s goals; communicated constructive feedback; evaluated growth and evolved challenges; and resolved interpersonal conflictsTechnical skills: - Investigated phenotype, trafficking, and function of subsets of mononuclear phagocytes and T lymphocytes through immunophenotyping (12-color FACS*), intra-vital microscopy (multiphoton*, microCT), protein and nucleic acid quantification (multiplex protein assay, ELISA, qPCR), and various in vitro cell activity assays- Achieved proficiency with pre-clinical rodent models of musculoskeletal and cutaneous injury/repair (incl. mouse rotator cuff*)- Employed various histological tissue analyses to evaluate vascular remodeling and tissue repair - Quantified controlled release of protein and small molecule therapeutics through analytical chemistry (HPLC, mass spec)*Indicates: Developed protocols that were adopted by lab

Champaign, Il, Us

Research focus + Cancer cell mechanical signaling, genetically encoded biosensors, and real-time laser microscopy

Doctor Of Philosophy - Phd, Bioengineering And Biomedical Engineering

Bachelor Of Science (B.S.), Engineering Physics